ArticleScientific reports2025
Sustainable UV approaches backed by one step extraction procedure for quantifying the newly released mirabegron and silodosin mixture in urine.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mirabegron (MIR) and silodosin (SIL) have recently been combined in a single pill to significantly enhance the effectiveness of treating detrusor hyperactivity with impaired contractility (DHIC), leading to appreciable improvements in symptoms associated with overactive bladder. Additionally, this combination effectively manages lower ureteric stones and improves patient outcomes with no significant side effects, especially in elderly patients. Accordingly, this study introduces two UV techniques for analyzing MIR and SIL in their mixtures (pure and commercial mixtures). These techniques were backed by a one-step salting-out liquid/liquid extraction (SALLE) procedure for quantifying MIR and SIL in urine samples without matrix interference. The proposed UV techniques succeeded in resolving the superimposed MIR's and SIL's UV spectra by employing straightforward mathematical filtration. The UV techniques were Fourier self-deconvolution (FSD) and induced dual-wavelength (IDW) techniques, with linearities of (50-350) µg/mL for MIR and (5-100) µg/mL for SIL. The applied techniques were verified following the International Council for Harmonisation (ICH) directives and were statistically evaluated against the published technique, with no noteworthy differences found. The applied techniques' practicality (blueness), whiteness, and greenness were appraised utilizing various metrics. Per the preceding, the applied approaches have been proven to be sustainable, delicate, and appropriate for quality control (QC) testing. Also, backing the applied approaches with the SALLE procedure enables precise monitoring of MIR and SIL in miscellaneous biological fluids with excellent recoveries, presenting an inventive approach for further bioanalytical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.